Fenwick represented Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, in its initial public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,500,000 additional shares of common stock, at a public offering price of $16 per share.
The shares began trading on the Nasdaq Global Market on May 27 under the ticker symbol DAWN. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, were $184 million.
J.P. Morgan, Cowen and Piper Sandler acted as joint bookrunning managers for the offering. Wedbush PacGrow acted as lead manager for the offering. More information can be obtained from the company's announcement.
The Fenwick transaction team included corporate partners Effie Toshav, Robert Freedman, Julia Forbess and Ryan Slunaker and associates Eugene Karlik, Darius Alam, Myles Gutenkunst, Adam Conway, Tim Wilson and Alexej Ladonnikov; executive compensation and employee benefits partner Marshall Mort and associates Jonathan Stephenson and Christophe Delrieu.